Ensayos que prueban un tratamiento · 13 estudios
Aquí se prueba algo nuevo: un medicamento, una pauta o un procedimiento. Si participas, recibes el tratamiento en estudio o el estándar, y el equipo te sigue de cerca.
Cáncer de mama precoz ER+/HER2− tras al menos dos años de tratamiento hormonal: camizestrant
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Para: Breast Cancer, Early Breast Cancer
11 centros: Baia Mare · Brașov · Cluj-Napoca · y 8 más
Fase 3Ver la ficha oficial ↗NCT05774951
Título original del registro
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Cáncer de mama triple negativo sin tratamiento previo: izalontamab brengitecan comparado con la quimioterapia
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.
Para: Breast Neoplasms
9 centros: Bistrița · București · Institutul Oncologic Cluj, Cluj-Napoca · y 6 más
Fase 2Ver la ficha oficial ↗NCT06926868
Título original del registro
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Cáncer de mama precoz ER+/HER2− con riesgo alto de recaída: elacestrant comparado con el tratamiento hormonal estándar
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Para: Breast Cancer
6 centros: Spitalul Clinic Filantropia, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Oncolab - Medical Oncology, Craiova · y 3 más
Fase 3Ver la ficha oficial ↗NCT06492616
Título original del registro
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Cáncer de mama avanzado HR+/HER2−, primera línea: gedatolisib
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Para: Breast Cancer
6 centros: Centrul de Oncologie Sf Nectarie - Medical Oncology, Baia Mare · Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, București · Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti, Cluj-Napoca · y 3 más
Fase 3Ver la ficha oficial ↗NCT06757634
Título original del registro
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Cáncer de mama triple negativo: sacituzumab tirumotecan solo y con pembrolizumab
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Para: Triple Negative Breast Neoplasms
6 centros: Spitalul Clinic Filantropia, București · Institutul Oncologic Cluj, Cluj-Napoca · S.C. Radiotherapy Center Cluj S.R.L, Comuna Floresti · y 3 más
Fase 3Ver la ficha oficial ↗NCT06841354
Título original del registro
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Cáncer de mama avanzado ER+/HER2−, primera línea: palazestrant con ribociclib
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Para: Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
6 centros: București · Cluj-Napoca · Craiova · y 3 más
Fase 3Ver la ficha oficial ↗NCT07085767
Título original del registro
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Cáncer de mama metastásico: lasofoxifeno con abemaciclib comparado con fulvestrant con abemaciclib
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.
The main question the study aims to answer is:
• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Para: Metastatic Breast Cancer
5 centros: Centrul Medical Focus, București · Radiotherapy Center Cluj, Cluj-Napoca · Onco Clinic Consult SA, Craiova · y 2 más
Fase 3Ver la ficha oficial ↗NCT05696626
Título original del registro
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
Evaluation of the potential incremental efficacy and safety of inavolisib in the neoadjuvant endocrine treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.
Para: HER2-positive Breast Cancer
4 centros: Spitalul Clinic Filantropia, București · Institutul Oncologic "Prof. Dr. Ion Chiricuta", Cluj-Napoca · Institutul Regional de Oncologie Iasi, Iași · y 1 más
Fase 2Ver la ficha oficial ↗NCT05306041
Título completo
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
Cáncer de mama: sacituzumab tirumotecan, un medicamento en estudio
Researchers are looking for new ways to treat types of breast cancer that are both:
* High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment
* Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.
Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread.
The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy:
* Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy
* Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Para: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
4 centros: Spitalul Clinic Filantropia, București · SC Radiotherapy Center Cluj SRL, Cluj-Napoca · Institutul Regional de Oncologie, Iași · y 1 más
Fase 3Ver la ficha oficial ↗NCT06966700
Título original del registro
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Cáncer de mama HER2 positivo: una vacuna peptídica probada para prevenir la recaída
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A\*02 positive and HER2/neu positive subjects.
Para: Breast Cancer
3 centros: Clinica Neolife Băneasa București, București · Institute of Oncology "Prof Dr Ion Chiricuta", Cluj-Napoca · Oncomed SRL - Oncology Center, Timișoara
Fase 3Ver la ficha oficial ↗NCT05232916
Título original del registro
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Cáncer de mama: sacituzumab tirumotecan solo y con pembrolizumab
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Para: Breast Neoplasms
3 centros: Spitalul Clinic Filantropia, București · Institutul Oncologic Cluj, Cluj-Napoca · SC Radiotherapy Center Cluj SRL-Oncologie Medicala, Florești
Fase 3Ver la ficha oficial ↗NCT06312176
Título original del registro
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Para: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
3 centros: Oncolab SRL, Craiova · Victoria Hospital SRL, Iași · Asociatia Oncohelp, Timișoara
Fase 3Ver la ficha oficial ↗NCT06982521
Título completo
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Linfedema crónico relacionado con el cáncer de mama: microcirugía comparada con el tratamiento conservador
The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)
Para: Lymphedema, Breast Cancer
Un centro: Institute of Oncology ''Prof. Dr. Ion Chiricuță'' of Cluj-Napoca, Cluj-Napoca
Sin faseVer la ficha oficial ↗NCT05890677
Título original del registro
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
Fuente: ClinicalTrials.gov, el registro público de la National Library of Medicine de Estados Unidos. Datos obtenidos el 13 oct 2026.
